In ovarian cancer, a tumour that remains largely confined to the peritoneal cavity for most of its natural history, there is both experimental and clinical evidence for a fairly steep cytotoxic dose-response curve to a number of chemotherapeutic agents (Alberts et al., 1985; Levin & Hryniuk, 1987) . Over the past decade the potential benefits and limitations of i.p. drug delivery have been defined and taken into consideration in the development of clinical trials. One of the basic principles of i.p. treatment is the free surface diffusion of the drug into the tumour (Los et al., 1989 (Los et al., , 1990 . It is therefore critical that the drug actually reaches the tumour (Dunnick et al., 1979; Howell et al., 1982) . The determining factor is the penetration of the drug into the tumour. This issue has been examined extensively for several cytostatic drugs (Ozols et al., 1979; West et al., 1980; Kerr & Kaye 1987; Los et al., 1990) . The universal conclusion of these studies has been that, in spite of the high local drug concentrations achieved in the peritoneal cavity after i.p. treatment, the direct penetration of cytostatic drugs from the peritoneal cavity into the tumour is limited, ranging from several cell layers to 1-3 mm from the peritoneal surface (los & McVie 1991) .
In view of this limited pentration capacity of cytostatic drugs, the efficacy of the i.p. treatment will probably also depend on the drug delivered by the systemic circulation. In essence only i.p.-administered drugs for which the doselimiting toxicity is systemic will show no reduction in the amount of drug reaching the tumour by capillary flow. cDDP and CBDCA, for example, both have systemic sideeffects after i.p. treatment, limiting the amount of drug that can be administered (Howell et al., 1982; Elferink et al., 1988) . Pharmacokinetic studies in rodents and patients have demonstrated that tumour exposure by the systemic circulation is similar after i.v. or i.p. administration of cDDP or CBDCA (Ten Bokkel Huinink, 1985; Elferink et al., 1988; Los et al., 1989 Los et al., , 1991a . Since the pharmcokinetic studies, clinical studies on response have suggested that i.p. therapy is an acceptable option for patients with persistent residual ovarian cancer who fail to respond to systemic treatment. Patients with microscopic disease or with lesions <0.5cm appear to experience prolonged disease-freee survival following i.p. chemotherapy (Markman, 1991) . However, even in this subgroup patients will finally relapse.
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A potential way of improving the efficacy of i.p. chemotherapy is the application of hyperthermia during i.p. chemotherapy. The rationale behind this approach is the observations that heat induces ultrastructural changes in cell membranes (Arancia et al., 1989) , will increase membrane transport of drugs (Hahn et al., 1975) and can alter cellular metabolism (Hahn & Shiu, 1983) , which can lead to an increased drug uptake into tumour tissue (Los et al., 1991b (Los et al., , 1992 . Furthermore, in vitro studies have demonstrated enhanced cytotoxicity of cDDP and CBDCA by hyperthermia (Fisher & Hahn, 1982; Herman et al., 1988) .
In view of the potentiating effects of heat on the cDDP and CBDCA cytotoxicity, and in addition to previous pharmacokinetic studies performed in a peritoneal tumour model (Los et al., 1991b (Los et al., , 1992 , we have tested the efficacy of regional hyperthermia during i.p. treatment for tumours restricted to the peritoneal cavity. We therefore assessed the cDDP or CBDCA DNA adduct formation in peritoneal tumours and, most importantly, the tumour growth delay of peritoneal tumours in our tumour model in the rat after i.p. treatment with cDDP or CBDCA combined with regional hyperthermia. This led to an evaluation of the role of regional hyperthermia of the abdominal cavity in i.p. treatment of cancers restricted to the peritoneal cavity.
Materials and methods
Rats and drugs Male WAG/Rij rats (8-12 weeks old; 250-300 g) were obtained from the animal department of The Netherlands Cancer Institute. The animals were kept in a temperaturecontrolled room on a 12 h light-12 h darkness schedule and fed standard rat chow and tap water ad libitum. cisDiamminedichloroplatinum(II) (cDDP) and cis-diammine (1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA) were obtained from Bristol Myers (Weesp, The Netherlands). cDDP-and CBDCA-containing vials were stored at room temperature.
Tumor model
The tumour used (CC531) is a well-defined transplantable rat colonic adenocarcinoma (Marquet et al., 1984) , with an in vitro doubling time of 16 h. The tumour also grows in vivo when implanted subcutaneously and intraperitoneally. (Los et al., 1989 Hyperthermia treatment Rats were anaesthetised by i.m. injection of 0.05 ml (6 mg kg-') Rompun followed by 50 mg kg-' Ketalar 12 min later. Then the rats were positioned in a thermostatically controlled water bath at 41.5°C and cDDP or CBDCA was administered i.p. in a 0.9% sodium chloride solution at a temperature of 41.5°C (20 ml). The temperature in the peritoneal cavity of the animal steadily increased from around 39°C to 41.5°C in about 30 min. The duration of the heat treatment at 41.5°C was 60 min. During treatment, i.p. temperatures were monitored every 5 min using copperconstant thermocouple probes (IT-18, diameter 0.62 mm, Sensortek, USA) at three locations in the peritoneal cavity (near the bladder, the spleen and right kidney). In addition to the temperatures in the peritoneal cavity, the rectal temperature at a distance of 6 cm from the anal ring and the intraoesophageal temperature were monitored.
Toxicity studies Toxicity studies were performed in order to determine the MTD for cDDP and CBDCA in combination with regional hyperthermia. The doses for cDDP were 3, 3.5, 5 and 7 and 2, 3.5 and S mg kg' at 37°C and 41.5°C respectively. The CBDCA dose was 30 mg kg-' at both 37°C and 41 .5°C. The MTD for CBDCA at normal body temperature is 30 mg kg-' (Los et al., 1993a) . Since nephrotoxicity and myelosuppression are dose limiting, we determined plasma creatinine levels and the nadir for thrombocytes, leucocytes and erythrocytes and used these data together with weight loss to determine the MTD. At fixed time points (day 0, 5, 7, 10, 14, up to 52 days), blood samples were taken and creatinine, thrombocyte, leucocyte and erythrocyte levels were determined.
Determination of tumour platinum concentrations Rats with multiple peritoneal tumours (2-5 mm in diameter) were treated i.p. with cDDP (3.5 or 5 mg kg-') or with CBDCA (30 mg kg-') with or without adbominal hyperthermia. After 24 h tumours were collected and prepared for platinum measurements.
A Varian model AA40 atomic absorption spectrometer with a GTA 96 graphite tube atomiser (with Zeeman background correction) was used for analysis. Sample preparation and the fast atomic absorption spectrometry procedure have been described elsewhere (Los et al., 1990) .
Immunocytochemical assay Peritoneal tumours were fixed in Kryofix (Merck, Darmstadt, Germany) and embedded into K-plast (Medin, Giessen, Germany). Two-micron sections were cut and mounted on slides, coated with a solution of chromium(III)-potassium sulphate (0.1%) and gelatin (1%). The immunocytochemical procedure was carried out essentially as described by Terheggen et al. (1987) . Briefly the staining procedure was as follows: sections were treated with methanol-hydrogen peroxide (to inactivate endogenous peroxidase) and ethanol-sodium hydroxide (to denature the DNA and/or to increase the accessibility to antibodies). Non-specific binding of the anti-cDDP DNA serum (NKI-A59) antibody was prevented by adding calf thymus (CT) DNA (Boehringer, Mannheim, Germany) to the incubation. The NKI-A59 antibodies bound to the DNA in the last step were visualised by double staining.
The characteristics of the rabbit antiserum NKI-A59 against cDDP-modified calf thymus DNA (platinum-nucleotide ratio 6.7 x 10-2) have been described by Terheggen et al. (1991) . NKI-A59 (applied without further purification), goat anti-rabbit immunoglobulin (Campro Benelux, Elst, The Netherlands) and rabbit PAP complex (American Qualex, La Miranda, USA) were used at dilutions of 1:2,500 1:600 and 1:3,000 respectively. All sera were diluted in phosphate buffer (pH 7.4) containing 10 mM potassium dihydrogen phosphate/ 140 mM sodium chloride, 10% normal goat serum (NGS) and 0.04% Triton X-100 (BDH, Poole, UK). Scherer et al., 1988) . The integrated optical density of a selected area was expressed in arbitrary units. In each slide the nuclear staining density of ten randomly selected areas, corresponding to 10-20 nuclei each, was measured.
Sensitivity of CC531 to cDDP and CBDCA The sensitivity of CC531 cells to cDDP and CBDCA at different temperatures was tested by clonogenic assay. CC531 cells were harvested as described before and counted. Cells in a single-cell suspension were plated in six-well tissue culture clusters (Costar, Cambridge, UK) at 150 cells per well in conditioned medium. After 24 h of incubation at 37C, the cells being attached to the plates, 2 fig ml-' cDDP (IC40) or 100 gg ml-' CBDCA (ICm) was added. The culture clusters were incubated at 370C, 38.5°C, 400C, 41.50C or 43°C for 75 min (15 min was needed to reach the proper temperature). After incubation, cells were washed twice with phosphatebuffered saline (PBS) and 3 ml of fresh medium was added. All plates were returned to the incubator and incubated for 7-10 days for the development of colonies. Colonies were fixed with ethanol, stained with crystal violet for 10 min, counted and related to the control.
Tumour growth delay Rats with a small solid tumour (4-5 mm in diameter) in the peritoneal cavity were treated i.p. with 3.5 mg kg-' cDDP at 37C, with 2.8 mg kg-cDDP at 40°C, 41°C and 41.50C or with 30mg kg-' CBDCA at 37°C, 40°C, 40.50C and 41.50C.
The tumour was located on the peritoneal wall left of the median close to the transitions of the upper and lower quadrants or on adipose tissue surrounding the spermatic cord high in the pelvis. Tumour measurements were performed every 2 weeks by laparotomy. The tumour size was assessed by measuring the three perpendicular diameters of the tumour with digital calipers. The geometric mean of the three values was then calculated (Begg, 1987) . Tumour growth delay was defined as the time required to regrow to a predetermined size (mean diameter of 10 mm) of the treated group minus the control group. The growth delay ratio (GDR) was calculated by the TGD at a certain temperature divided by the TGD at 37°C. Statistics Student's t-test or the Wilcoxon test were used to study differences; P-values <0.05 were considered to indicate significant differences.
Results
Toxicity studies Toxicity studies were performed in order to determine the MTD of i.p. cDDP or CBDCA treatment combined with hyperthermia of the peritoneal cavity (41.5°C). Since nephrotoxicity and myelosuppression are most prominent and dose limiting, plasma creatinine levels and the nadir of erythrocytes, leucocytes and thrombocytes were used to determine the MTD for cDDP and CBDCA treatment respectively. Increasing the temperature from 37°C to 41.5°C resulted in increased plasma creatinine levels after cDDP treatment (Figure 1) . MTD or cDDP at 37C was 5 mg kg-' with a plasma creatinine level of 320 ± 69 ng ml-'. A dose reduction of 33.3% (3.5 mg kg-') at 41.5°C was required to obtain similar creatinine levels as those at 37°C (Figure 1 ). For CBDCA the nadir of erythrocytes, leucocytes and thrombocytes was determined ( Erythrocytes (x 1012 1-1)
7.9 ± 0.5 4.1 ± 3.5 5.9 ± 0.3
Thrombocytes (x1091-') 659±243 351±200 106±53* n = five rats ± s.d. The nadir was reached 7-11 days after treatment; measurements were performed at day 5, 7, 10, 14 up to 52 days.
Data presented in this table represent measurements performed on day 7 and 10 (no significant differences between treatments at 37°C and 41.5°C, except for thrombocytes, *P<0.05).
with i.p. cDDP and CBDCA (Figure 2 ). (Figure 4 ). Tumour response The effect of regional hyperthermia on the peritoneal tumour growth was studied up to 50 days after heat treatment. Figure 5 demonstrates the tumour size at fixed time points after heat treatment. It is clear that a single heat treatment with temperatures up to 41.5°C does not affect tumour growth. However, tumour growth delay of peritoneal tumours was induced after i.p. treatment with both cDDP and CBDCA at different temperatures ( Figure 6 ). Tumour growth delay was determined when tumours had reached four times the initial size (geometric mean of 10 mm). For this purpose tumour growth was followed for 63 days. An Table II Tumour growth delay   Tumour growth delaja at   Drugs   37C  40°C  41°C 41.5°C cDDP 4 ± 4 13 ± 2 19 ± la >40b CBDCA 6 ± 8 6 ± 5 18 ± 12a 22 ± lOb aTumour growth delay (days ± s.d.) was determined in at least two independent experiments (n> 4) and defined as the time (days) required to regrow to a predetermined size (mean diameter 10 mm) after treatment with either cDDP, 3.5 mg kg-' or 2.8 mg kg-' at 37°C or 40°C and above respectively, or CBDCA (30 mg kg-'). n = at least four tumour-bearing rats. bTGD differs significantly compared with the treatment at 37°C (Wilcoxon test, P<0.05).
increase in the temperature from 3TC to 40°C led to tumour growth delay of 4 ± 4 to 13 ± 2 days after cDDP treatment (Table II) . A further increase of the temperature to 41.5°C resulted in a growth delay of more than 40 days, resulting in a growth delay ratio (TGD 41.5°C/TGD 37C) of more than 10. Also, for CBDCA a similar pattern of tumour growth delay is demonstrated ( Figure 6 , Table II ). Tumour growth delay increased from 6 ± 8 at 37C up to 22 days at 41.5°C, resulting in a GDR of 3.6. These data indicate that cDDP treatment is potentiated to a greater extent than CBDCA treatment by temperatures in the range of 40-41.5°C.
Discussion
In previous studies we have shown that i.p. chemotherapy with cDDP or CBDCA in combination with abdominal hyperthermia leads to pharmacokinetic changes, higher uptake of cDDP or CBDCA into peritoneal tumours and higher cytotoxicity in vitro, using equimolar drug concentrations at 37C and 41.5°C. In addition to these findings, we now demonstrate that i.p. chemo-hyperthermia with cDDP or CBDCA at MTD levels leads to increased cDDP and CBDCA DNA adducts in peritoneal tumours and consequently to an increase in peritoneal tumour growth delay.
It is demonstrated that abdominal hyperthermia can be consistently and safely achieved and maintained in the rat using a simple heating system (Los et al., 1991b (Los et al., , 1992 . The only disadvantage of this heating system is that a relatively large part of the rat body is heated in the water bath (Los et al., 1991 b) . This method results in a higher systemic temperature than in other animals models (Spratt et al., 1980; Zakris et al., 1987) , which is certainly lower than that achieved with whole-body hyperthermia (Riviere et al., 1986; Wondergem et al., 1988) . The higher systemic temperatures obtained in our rat model seemed to increase nephrotoxicity more than myelosuppression (Figure 1 , Table I ). This might be explained by the fact that the kidney lies in the heated area and, since the whole-body temperature is also raised, the blood will cool down the well-perfused tissues less than at normal body temperature. The increased temperature in the peritoneal cavity consistently led to enhanced nephrotoxicity (Wondergem et al., 1988; Los et al., 1991b) . A dose reduction of cDDP was, therefore, unavoidable. In situ heating of the peritoneal cavity by a more regional approach than used in our system will probably provide a small increase in systemic temperature not exceeding the arterial temperature. Extensive thermometry in patients treated with i.p. CBDCA in combination with abnominal hyperthemia demonstrated that regional hyperthermia delivered by the annular phase and amplitude-controlled applicator led to peritoneal tumour temperatures up to 42°C, while the systemic temperature did not increase above 38.5°C (Formenti et al., 1992) . This clinical study demonstrates that local temperatures in the peritoneal cavity can be raised while systemic temperatures show only a minor increase. Recently we demonstrated in the same model that the increase in platinum concentration in normal tissues after the combined treatment remained behind of that in tumours. Except in the kidney, in the case of cDDP treatment combined with hyperthermia, no other severe increase in tissue platinum concentration resulting in toxicity could be observed (Los et al., 1991b (Los et al., , 1992 (Konings et al., 1988) . Increasing the temperature may result in an increased permeability of the cell membrane (Arancia, 1989 For i.p. therapy to show an advantage over i.v. therapy, the drug is required to diffuse inward from the periphery into the intraperitoneal tumour mass. By combinding ip. cDDP or CBDCA chemotherapy with abdominal hyperthermia one would expect a better penetration capacity of the cytostatic drug. We hypothesise therefore that one of the factors involved in the increase in intratumoral platinum concentration, resulting in an increase in tumour growth delay for both cDDP and CBDCA, is better penetration of cDDP and CBDCA into tumour tissue. This hypothesis is partly supported by previous work in which the spatial platinum dis-tribution in peritoneal tumours after i.p. cDDP treatment at 41.5°C was more homogeneous than after treatment at 370C (Los et al., 1991b) . However, such an effect was not demonstrated for CBDCA. Previous work has demonstrated that abdominal hyperthermia augments intratumoral platinum concentrations regardless of whether CBDCA is delivered i.p. or i.v. (Los et al., 1992) . Nevertheless, a rationale for pursuing the i.p. route for CBDCA was given by concerns over possible enhanced nephrotoxicity. It was demonstrated that Pt concentrations in the kidney are increased more after i.v. chemo-hyperthermia treatment than after i.p. chemohyperthermia (Los et al., 1992) .
In addition, other groups have now shown that hyperthermia increases the cytotoxicity of several chemotherapeutic agents, such as nitrogen mustard, cisplatin (cDDP), carboplatin (CBDCA), bleomycin and mitomycin (Hahn, 1979; Barlogie et al., 1980; Dahl, 1988) . Fujimoto et al. (1988) observed in an in vivo model of gastric cancer xenotransplanted into nude mice that hyperthermia plus mitomycin C led to a delay in tumour growth and a significantly greater effect on DNA synthesis than hyperthermia alone. The same group also demonstrated that gastric cancer patients with peritoneal dissemination treated with an intraperitoneal hyperthermic perfusion with mitomycin C had a longer disease-free survival period than after systemic mitomycin C alone (Kokubun et al., 1991) . Taking into account the relative magnitude of the effects on tumours and normal tissues, no tissues other than the kidney seem to be negatively affected. Previous findings together with those presented in the present study suggest that the combination of chemotherapy and hyperthermia may be beneficial.
